Aim: To evaluate the effects of short-term restriction of dietary protein intake (DPI) supplemented with keto acids on hyperphosphatemia in maintenance hemodialysis (MHD) patients. Methods: Forty MHD patients with uncontrolled hyperphosphatemia were randomized to either low DPI with keto acid-supplemented (sLP) or normal DPI (NP) group for 8 weeks. After 8 weeks, the sLP group was shifted to NP for another 8 weeks. Low-protein diet (LPD) was individualized with total caloric intake 30–35 kcal/kg/day, protein intake of 0.8 g/kg/day and phosphate intake of 500 mg/day. Keto acids were supplied in a dosage of 12 pills per day. Calcium phosphorous metabolism index and nutritional index (serum albumin, total protein, somatometric measurements, 3-day diaries and Mini-Nutritional Assessment score) were recorded. C-reactive protein, CO2 combining power and Kt/V were measured to evaluate the inflammation, metabolic acidosis and dialysis adequacy, respectively. Results: Serum phosphorus level and calcium-phosphate product were significantly decreased at the end of the first 8 weeks in the sLP group compared to the basal value and the NP group (p < 0.001). No difference was observed in C-reactive protein, Kt/V and nutritional index, while CO2 combining power was significantly higher at week 8 in the sLP group (p < 0.001). Conclusion: Short-term restriction of DPI supplemented with keto acids could decrease hyperphosphatemia and calcium-phosphate product, while keeping stable nutritional status among MHD patients.

1.
Block GA, Klassen PS, Lazarus JM, et al: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–2218.
2.
Giachelli CM: Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959–2964.
3.
Paul M, Jiang H, Brad CA, et al: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005;16:529–538.
4.
National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3):S1–S201.
5.
Young EW, Akiba T, Albert JM, et al: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:34–38.
6.
Reddy V, Symes F, Sethi N, et al: Dietitian-led education program to improve phosphate control in a single-center hemodialysis population. J Ren Nutr 2009;19:314–320.
7.
Achinger SG, Ayus JC: The role of daily dialysis in the control of hyperphosphatemia. Kidney Int Suppl 2005;95:S28–S32.
8.
Kuhlmann MK: Practical approaches to management of hyperphosphatemia: can we improve the current situation? Blood Purif 2007;25:120–124.
9.
Uribarri J: Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial 2007;20:295–301.
10.
Hsu CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641–649.
11.
Coladonato JA: Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 2005;16:S107–S114.
12.
Alfrey AC, Mishell JM, Burks J, et al: Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972;18:257–261.
13.
Alfrey AC, Legendre GR, Kaehny WD: The dialysis encephalopathy syndrome: possible aluminum intoxication. N Engl J Med 1976;294:184–188.
14.
Pierides AM, Edwards WG, Cullum UX, et al: Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980;8:115–124.
15.
Goodman WG, Goldin J, Kuizon BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478–1483.
16.
Moe S, Drueke T, Cunningham J, et al: Definition, evaluation and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945–1953.
17.
Navaneethan SD, Palmer SC: Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;54:619–637.
18.
Molony DA, Murthy B: Accumulation of metals and minerals from phosphate binders. Blood Purif 2005;23(suppl 1):2–11.
19.
Rufino M, de Bonis E, Martin M, et al: Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 1998;(suppl 3):S65–S67.
20.
Riedel E, Nundel M, Hampl H: α-Ketoglutarate application in hemodialysis patients improves amino acid metabolism. Nephron 1996;74:261–265.
21.
Schaefer K, Herrath D, Asmus G, et al: The beneficial effect of keto acids on serum phosphate and parathyroid hormone in patients with chronic uremia. Clin Nephrol 1988;30:93–96.
22.
Ikizler TA, Wingard RL, Harvell J, et al: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999;55:1945–1951.
23.
Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al: Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 2005;20:1880–1888.
24.
Kopple JD: National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001;37(suppl 2):S66–S70.
25.
Michel A, Philippe C, Valerie DP, et al: Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet. J Am Soc Nephrol 2000;11:708–716.
26.
Klahr S, Levey AS, Beck GJ, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330:877–884.
27.
Mahmoud MD, Bouche V, Collin P, et al: Effects of keto-analogues on phosphocalcic and amino acid metabolism in dialysed patients: a crossover study. Int J Artif Organ 1989;12:692–696.
28.
Wernermann J: α-Ketoglutarate in the treatment of postoperative and critically ill patients. Clin Nutr 1993;12:58–59.
29.
Cynober L: Ornithine α-ketoglutarate in nutritional support. Nutrition 1991;7:313–322.
30.
Barsotti G, Morelli E, Guiducci A, et al: Reversal of hyperparathyroidism in severe uremics following a very low-protein and low-phosphorus diet. Nephron 1982;30:310–313.
31.
Barsotti G, Lazzeri M, Cristofano C, et al: The role of metabolic acidosis in causing uremic hyperphosphatemia. Miner Electrolyte Metab 1986;12:103–106.
32.
Combe C, Aparicio M: Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 1994;5:1381–1386.
33.
KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76(suppl 113):S1–S130.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.